Literature DB >> 23825860

Ventricular premature contractions associated with iloperidone.

Rashmin Achalia1, Chittaranjan Andrade.   

Abstract

Typical and atypical antipsychotic drugs are known to block potassium repolarization channels, prolong the QTc interval, and thereby predispose to ventricular tachyarrhythmias. We report a young male schizophrenic patient who experienced clinically significant and symptomatically distressing ventricular premature contractions (VPCs) in close temporal relation with iloperidone (8-16 mg/day) treatment; there had been no VPCs with prior exposure to risperidone, trihexyphenidyl, and olanzapine, nor with subsequent exposure to asenapine. We hypothesize that the VPCs may have been triggered by an alpha 2c receptor blockade-mediated cardiostimulatory action associated with iloperidone.

Entities:  

Keywords:  Adverse effects; antipsychotic drugs; cardiac arrhythmia; heart; iloperidone; ventricular premature contractions

Year:  2013        PMID: 23825860      PMCID: PMC3696249          DOI: 10.4103/0019-5545.111464

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


INTRODUCTION

Many antipsychotic drugs block potassium repolarization channels, prolong the QTc interval, and increase the risk of ventricular tachyarrhythmias.[12] For possibly the first time in literature, we report clinically distressing ventricular premature contractions (VPCs) associated with iloperidone treatment.

CASE REPORT

A 29-year-old male with a 9-month history of paranoid schizophrenia had failed to tolerate trials of risperidone (6 mg/day) with trihexyphenidyl (4 mg/day) and, later, olanzapine (10 mg/day); the former because of extrapyramidal symptoms, and the latter because of marked (12 kg) weight gain. He was therefore switched to iloperidone 2 mg/day. The dose was stepped up to 8 mg/day, and then to 16 mg/day. The antipsychotic response to iloperidone was good, but with dosing above 8 mg/day, he reported palpitations and breathlessness with symptoms present even at rest. A physician diagnosed and counseled him for anxiety, apparently because his ECG was normal. However, 7 days later, progressive exacerbation of symptoms led him to visit a cardiologist. After investigations that included a 2D echocardiogram and color doppler study, VPCs were diagnosed. The frequency of the VPCs could not be determined because diagnosis was based on observation during 2D echocardiography and not on ECG. Iloperidone was abruptly withdrawn and replaced by asenapine 10 mg/day. There was relief from the palpitations and breathlessness within 2-3 days of discontinuation of iloperidone. The patient remains well on asenapine 10 mg/day, and is free from cardiac symptoms at a 2-month follow up.

DISCUSSION

A PubMed search conducted on October 22, 2012, using the search terms ‘iloperidone’ and ‘heart’ identified only two hits. A preclinical study[3] demonstrated that iloperidone delays cardiac repolarization. A review[4] observed that no deaths or serious arrhythmias attributable to QTc prolongation had occurred in any of the iloperidone clinical trials. Another search, using the terms ‘iloperidone’ and ‘arrhythmia’, was not more helpful. The Naranjo Adverse Drug Reaction (ADR) Probability Scale[5] score was 5, indicating a probable relationship between iloperidone and VPCs. We suggest two important reasons why iloperidone was likely responsible for the VPCs. First, iloperidone not only inhibits cardiac repolarization[3] but also potently blocks alpha 2c receptors;[6] the latter pharmacodynamic action may have a cardiostimulatory effect, explaining the VPCs. Next, the onset and offset of VPCs were temporally related with the onset and offset of iloperidone treatment. In this context, we note that VPCs have been reported with other antipsychotics too, such as thioridazine[7] and quetiapine.[8] Interestingly, this patient received several different antipsychotics (risperidone, olanzapine, and asenapine) but experienced VPCs only with iloperidone. We conclude that ventricular premature contractions may be an uncommon adverse effect of iloperidone, and that this adverse effect may be mediated by iloperidone-induced alpha 2c adrenoceptor blockade.
  8 in total

Review 1.  Cardiac effects of antipsychotic medications.

Authors:  M Fayek; S J Kingsbury; J Zada; G M Simpson
Journal:  Psychiatr Serv       Date:  2001-05       Impact factor: 3.084

Review 2.  Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.

Authors:  Vincenzo Calderone; Lara Testai; Enrica Martinotti; Mario Del Tacca; Maria Cristina Breschi
Journal:  J Pharm Pharmacol       Date:  2005-02       Impact factor: 3.765

Review 3.  Iloperidone: a clinical overview.

Authors:  Leslie Citrome
Journal:  J Clin Psychiatry       Date:  2011       Impact factor: 4.384

4.  Quetiapine-induced frequent premature ventricular contraction.

Authors:  Akiko Deguchi; Masayuki Nakamura; Takehiro Hayashi; Akira Sano
Journal:  Gen Hosp Psychiatry       Date:  2012-01-13       Impact factor: 3.238

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.

Authors:  Patrick Vigneault; Sylvie Pilote; Dany Patoine; Chantale Simard; Benoit Drolet
Journal:  Pharmacol Res       Date:  2012-03-23       Impact factor: 7.658

7.  alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.

Authors:  Hans O Kalkman; Erika Loetscher
Journal:  Eur J Pharmacol       Date:  2003-02-21       Impact factor: 4.432

Review 8.  Sudden cardiac death secondary to antidepressant and antipsychotic drugs.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Expert Opin Drug Saf       Date:  2008-03       Impact factor: 4.250

  8 in total
  2 in total

Review 1.  Long-term efficacy and safety of iloperidone: an update.

Authors:  Jeffrey T Rado; Philip G Janicak
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-26       Impact factor: 2.570

Review 2.  Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.

Authors:  Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  Core Evid       Date:  2016-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.